● TIER 3 — Information onlyGRADE CImmune / thymic
KPV
α-MSH tripeptide. Research verification: Yes (TGA pending). 0 human study record(s) in the FitClinicMD studies database (plus 1 preclinical animal/lab record(s), shown for context only).
GOALS · Recovery / injury
FDA status
Not approved.
Compounding (503A/503B)
Removed from 503A Category 2 on ~Apr 22 2026 after nominations were withdrawn; PCAC voted Jul 23-24 2026 to recommend 503A bulks-list inclusion, but no rulemaking yet, so not lawfully compoundable and not in Category 1. FDA list:
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
NF-κB anti-inflammatory.
Human evidence · 1
Hydrogel delivery study (preclinical). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.
Reference only. This page summarizes publicly available regulatory and research information about KPV. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.